Nick Boyle, PhD, on Advantages of In Vivo CAR Therapies
The chief executive officer of Abintus Bio discussed the company’s in vivo approach and how it could help expand patient access to cell therapies.
Evan Zynda, PhD, on Optimizing Manufacturing to Increase Access to Cell Therapy
The senior scientist at Thermo Fisher Scientific discussed the company’s approach to scaling and strategic partnerships.
Treating Autoimmune Diseases With Smarter Cell Therapies
Karen Walker, chief technology officer, Kyverna Therapeutics, discussed the company’s CAR T-cell and regulatory T-cell technologies.
Gene Therapy Shows Promise in Leber Congenital Amaurosis
Significant improvements were reported in full-field stimulus testing.
Christine Coughlin, MD, PhD, on TRACK-NK Technology in Non-Small Cell Lung Cancer
The chief executive officer of Cytoimmune discussed the company’s technology platforms and programs.
Sid Kerkar, MD, on Developing CAR T Therapies Without Lymphodepletion Chemotherapy
The vice president of oncology and research and development at Exuma Biotech discussed the company’s platforms, including CAR-TaNK cells.
Wet AMD Gene Therapy Reduces Anti-VEGF Treatment Burden
Participants in the AAVIATE trial had up to an 85% decrease in treatment burden 6 months after treatment with RGX-314.
Working With the Community to Improve Patient Access to Trials, Therapies
Rob Richards, administrative director, cell therapy and transplant, University of Pennsylvania, discussed improving reach of gene therapy trials and therapies.
Marty Giedlin, PhD, on Advantages of Allogeneic NK Cell Therapy Approaches
The senior vice president of Technical Operations at Senti Biosciences discussed the company’s NK cell logic-gating platform and allogeneic approach.
Leaping the Next Hurdle in CAR T-Cell Therapies
Phil Cyr, Senior Vice President, Precision Value & Health, discussed challenges to tackle with CAR T-cell therapies.
Deyaa Adib, MD, on Safety Advantages of TAC T-Cell Therapy in Solid Tumors
The chief medical officer of Triumvira Immunologics discussed how TAC01-HER2 could address unmet needs in treating solid tumors.
Jeffrey Miller, MD, on Emerging Research With Natural Killer Cells
The deputy director of the Masonic Cancer Center discussed trends of presentations from ESMO 2022.
Switchable CAR-T Shows Promise in B-Cell Malignancies
Interim data showed a 78% overall response rate and a 67% complete response rate.
Zevor-Cel Yields 100% ORR in R/R Multiple Myeloma
Eleven patients in the LUMMICAR-2 trial were evaluable for preliminary efficacy analyses.
Deyaa Adib, MD, on Evaluating HER2 TAC T-Cell Therapy in Solid Tumors
The chief medical officer of Triumvira Immunologics discussed updates from the TACTIC-2 study presented at ESMO Congress 2022.
Jeffrey Miller, MD, on Engaging NK Cells in Solid Tumors
The deputy director of the Masonic Cancer Center discussed the preclinical findings of his study on a TriKE engager and NK cells.
Cilta-Cel Yields High MRD-Negativity Rates in Multiple Myeloma After Prior Anti-BCMA Treatment
Seven of 10 evaluable patients achieved minimal residual disease negativity after cilta-cel treatment.
David S. Hong, MD, on the SURPASS Clinical Trial and TCR T-cell Therapy in Solid Tumors
Hong presented data from the SURPASS clinical trial at the 2022 European Society for Medical Oncology (ESMO) Congress.
Weijia Fang, MD, and Guoqiang Ai, MD, on the Future of IMC001 in Gastric and Colorectal Cancer
Fang commented on a limitation of the clinical trial pointed out at the European Society for Medical Oncology (ESMO) 2022 Congress.
Weijia Fang, MD, and Tianhang Luo, MD, on EpCAM-Targeted CAR-T Therapy in Advanced Colorectal and Gastric Cancer
Fang recently presented at the European Society for Medical Oncology (ESMO) 2022 Congress.
IL13Rα2 Universal CAR T Therapy Shows Antitumor Activity in Recurrent Glioma
MT026 had an overall response rate of 83.3% in a first-in-human, investigator-initiated trial.
SNK01/Checkpoint Inhibitor Combo Yields Sustained Remission in Advanced SRC Sarcoma Case
The FDA authorized the natural killer cell therapy combo for compassionate use.
Phase 1 Clinical Trial Will Assess CAR-T With Genetic and Epigenetic Reprogramming for Solid Tumors
Improved functional activity compared to ROR-1-targeted CAR-T therapies without the 2 forms of reprogramming was demonstrated in preclinical studies.
Oncolytic Virus T-VEC Demonstrates Long-Term Benefits in Melanoma
The 5-year relapse-free survival rate was 22.3% with T-VEC prior to surgery, compared with 15.2% for surgery alone.
EpCAM-Targeted CAR-T Therapy Shows Promise in Colorectal, Gastric Cancer
Of the 8 treated patients who were evaluable, 6 patients had stable disease at Day 28.
TIL Therapy Superior to Ipilimumab for Progression-Free Survival in Unresectable Melanoma
Based on the findings, investigators are considering registration with the FDA and EMA.
TCR T-Cell Therapy Shows Efficacy Across MAGE-A4+ Solid Tumors
ADP-A2M4CD8 will be evaluated in the phase 2 SURPASS-3 trial initiating in late 2022 or early 2023.
DdBCMA-Targeted CAR-T Therapy Shows Clinical Activity in Multiple Myeloma
Among the 31 patients evaluable for efficacy analysis, ORR was 100%.
PD1 Knockout CAR T-Cell Therapy Well-Tolerated, Yields Durable Response in DLBCL
A phase 2 trial evaluated the therapy in patients with diffuse large B-cell lymphoma, B-acute lymphocytic leukemia, and follicular lymphoma.
CAR T/CARVac Therapy Yields Responses in Refractory Testicular Cancer
BNT211 showed encouraging responses in testicular cancer but less encouraging responses in ovarian cancer.
